CinDome Pharma raises $40m for gastroparesis treatment

CinDome Pharma has successfully secured an additional $40 million in a Series B funding extension, aimed at furthering the development of deudomperidone (CIN-102) as a potential long-term treatment for chronic gastroparesis. This latest round of financing was contributed by the company's existing investors, including Perceptive Advisors and CinRx Pharma. With this new infusion of capital, the total funds raised in the Series B round now stand at $59 million.

The new funding is expected to support the ongoing Phase II envision3D clinical trial of deudomperidone, which is currently being tested in adults suffering from diabetic gastroparesis. It will also help prepare CinDome for the crucial registrational trials that are necessary for the eventual approval and commercialization of the drug.

Gastroparesis is a medical condition characterized by delayed gastric emptying, affecting approximately 12 to 16 million people in the United States. This condition is becoming increasingly prevalent, largely due to rising diabetes rates. Presently, there are no FDA-approved long-term treatments for gastroparesis available in the US market.

Deudomperidone is a novel formulation of domperidone, a medication commonly used for nausea, vomiting, and gastroparesis in countries outside the United States. Due to safety concerns related to QT prolongation, domperidone has not been approved for sale in the US. However, deudomperidone has been specifically engineered to modify its pharmacokinetic profile, maintaining its efficacy while minimizing the associated cardiac risks.

In multiple clinical trials, deudomperidone has shown to be well-tolerated, with no drug-related adverse events or lab abnormalities reported by sponsors. Importantly, a thorough QT study demonstrated that deudomperidone had no significant impact on QT intervals even at doses higher than therapeutic levels. The drug also showed promising results in previous Phase IIa trials, where it demonstrated target engagement and a positive effect on gastric emptying time.

Dr. Jon Isaacsohn, founder and CEO of CinRx Pharma, expressed his gratitude for the continued support from investors: “This increased investment in CinDome extends our important, ongoing development activities and enables readiness for deudomperidone to enter late-stage trials. We are grateful for the continued support and partnership from Perceptive Advisors to advance this high-impact therapeutic and bring a new hope to people impacted by gastroparesis.”

By securing this additional funding, CinDome Pharma is poised to make significant strides in addressing a critical unmet medical need. Deudomperidone holds the potential to become the first FDA-approved long-term treatment for gastroparesis, offering new hope to millions of individuals suffering from this debilitating condition.